Innovent Biologics, Inc.

OTCPK:IVBX.F Stock Report

Market Cap: US$7.4b

Innovent Biologics Management

Management criteria checks 2/4

Innovent Biologics' CEO is Michael Yu, appointed in Jan 2011, has a tenure of 13.92 years. total yearly compensation is CN¥36.44M, comprised of 7.9% salary and 92.1% bonuses, including company stock and options. directly owns 6.53% of the company’s shares, worth $484.40M. The average tenure of the management team and the board of directors is 0.9 years and 3.3 years respectively.

Key information

Michael Yu

Chief executive officer

CN¥36.4m

Total compensation

CEO salary percentage7.9%
CEO tenure13.9yrs
CEO ownership6.5%
Management average tenureless than a year
Board average tenure3.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Michael Yu's remuneration changed compared to Innovent Biologics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-CN¥1b

Mar 31 2024n/an/a

-CN¥1b

Dec 31 2023CN¥36mCN¥3m

-CN¥1b

Sep 30 2023n/an/a

-CN¥1b

Jun 30 2023n/an/a

-CN¥1b

Mar 31 2023n/an/a

-CN¥2b

Dec 31 2022CN¥33mCN¥3m

-CN¥2b

Sep 30 2022n/an/a

-CN¥2b

Jun 30 2022n/an/a

-CN¥3b

Mar 31 2022n/an/a

-CN¥3b

Dec 31 2021CN¥26mCN¥3m

-CN¥3b

Sep 30 2021n/an/a

-CN¥2b

Jun 30 2021n/an/a

-CN¥1b

Mar 31 2021n/an/a

-CN¥1b

Dec 31 2020CN¥105mCN¥3m

-CN¥998m

Sep 30 2020n/an/a

-CN¥1b

Jun 30 2020n/an/a

-CN¥2b

Mar 31 2020n/an/a

-CN¥2b

Dec 31 2019CN¥76mCN¥3m

-CN¥2b

Compensation vs Market: Michael's total compensation ($USD5.00M) is below average for companies of similar size in the US market ($USD8.04M).

Compensation vs Earnings: Michael's compensation has increased whilst the company is unprofitable.

CEO

Michael Yu (60 yo)

13.9yrs

Tenure

CN¥36,444,000

Compensation

Dr. De-Chao Yu, also known as Michael, Ph.D. Co-Founded Innovent Biologics, Inc. in August 2011 and has been its Chairman and Chief Executive Officer since 2011. He served as its President at Innovent Biol...

Leadership Team

NamePositionTenureCompensationOwnership
De-Chao Yu
Co-Founder13.9yrsCN¥36.44m6.53%
$ 484.4m
Hao Xi Ede
Executive Director & Fund Managing Partnerless than a yearCN¥7.10m0.20%
$ 14.7m
Fei You
Chief Financial Officerless than a yearno datano data
Vivian Zhang
Chief People Officer5.4yrsno data0.020%
$ 1.5m
Min Liu
Chief Commercial Officerno datano datano data
Dongming Wang
Senior Vice President4.9yrsno datano data
Blake Salisbury
Senior Vice Presidentno datano datano data
Hui Zhou
Senior Vice Presidentless than a yearno datano data
Nageatte Ibrahim
Oncology Chief Medical Officerless than a yearno datano data
Samuel Suhua Zhang
Global Chief Business Officerless than a yearno datano data
Raj Dhodda
Senior Vice Presidentless than a yearno datano data
Yanju Wang
Joint Company Secretary6.5yrsno datano data

0.9yrs

Average Tenure

51yo

Average Age

Experienced Management: IVBX.F's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
De-Chao Yu
Co-Founder13.9yrsCN¥36.44m6.53%
$ 484.4m
Hao Xi Ede
Executive Director & Fund Managing Partnerno dataCN¥7.10m0.20%
$ 14.7m
Vivian Zhang
Chief People Officerless than a yearno data0.020%
$ 1.5m
Charles Leland Cooney
Member of CMC Strategic Advisory Board & Independent Non-Executive Director9.2yrsCN¥400.00k0.0028%
$ 205.4k
Lewis Lanier
Member of Scientific Advisory Board3.3yrsno datano data
I-Yin Hsu
Independent Non-Executive Director6.2yrsCN¥400.00k0.00039%
$ 28.9k
Erwin Vanhaecke
Member of CMC Strategic Advisory Boardno datano datano data
Kai-Xian Chen
Independent Non-Executive Director6.2yrsCN¥400.00k0.00033%
$ 24.5k
David LaPre
Member of CMC Strategic Advisory Boardno datano datano data
Shuyun Chen
Independent Non-Executive Directorless than a yearno data0.00067%
$ 49.7k
Lawrence Fong
Member of Scientific Advisory Board3.3yrsno datano data
Carlos Garcia-Echeverria
Member of Scientific Advisory Board3.3yrsno datano data

3.3yrs

Average Tenure

60yo

Average Age

Experienced Board: IVBX.F's board of directors are considered experienced (3.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 04:44
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Innovent Biologics, Inc. is covered by 53 analysts. 29 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Linda LuBOCI Research Ltd.
Wai Chak YuenBOCI Research Ltd.
Bo LiBofA Global Research